Are Major Depressive Disorder and Diabetes Mellitus Amyloidogenic Conditions?

Are Major Depressive Disorder and Diabetes Mellitus Amyloidogenic Conditions?

Author Baskaran, Anusha Google Scholar
Carvalho, Andre F. Google Scholar
Mansur, Rodrigo Barbachan Autor UNIFESP Google Scholar
McIntyre, Roger S. Google Scholar
Institution Queens Univ
Univ Hlth Network
Univ Fed Ceara
Universidade Federal de São Paulo (UNIFESP)
Univ Toronto
Abstract Major depressive disorder (MDD) and diabetes mellitus (DM) have reciprocal relationship and share common pathophysiological mechanisms in the central nervous system. Depression and diabetes negatively affect cognitive function and are independent risk factors for mild cognitive impairment and Alzheimers disease (AD). It has been hypothesized that alterations in the production and processing of amyloid beta (A beta) may be the principal pathological process in AD. Furthermore, it has been increasingly demonstrated that a long preclinical course precedes AD. A derivative of this observation is the hypothesis that a convergent pathophysiological substrate subserving MDD and DM may promote beta amyloid (A beta) deposition. The present paper will review evidence linking MDD and DM to A beta accumulation, with a particular emphasis on original reports that report on levels of A beta 40, A beta 42 and the A beta 40/42 ratio in plasma, serum, or cerebrospinal fluid of individuals with MDD and DM. The overarching goal herein is to press the point that MDD and DM are amyloidogenic and consequently represent modifiable risk factors for AD in later life. The prognostic intervention and prevention opportunity suggested by this notion is that: 1) increased rates of mood disorders and DM in an aging population will increase the population attributable risk for AD ascribed to these conditions, 2) improved outcomes in mood disorders and DM by effective treating to target may exert a salutary influence on underlying dementia promoting processes, 3) novel and repurposed medications that are capable of normalizing pathophysiological processes in MDD and DM could decrease the vulnerability towards AD.
Keywords Alzheimer's disease
beta amyloid
depression
diabetes
insulin
Language English
Sponsor AstraZeneca
Bristol-Myers Squibb
France Foundation
GlaxoSmithKline
Eli Lilly
Janssen-Ortho
Organon
Lundbeck
Pfizer
National Alliance for Research on Schizophrenia and Depression
National Institutes of Mental Health
Stanley Medical Research Institute
Shire
Date 2014-01-01
Published in Cns & Neurological Disorders-drug Targets. Sharjah: Bentham Science Publ Ltd, v. 13, n. 10, p. 1667-1676, 2014.
ISSN 1871-5273 (Sherpa/Romeo, impact factor)
Publisher Bentham Science Publ Ltd
Extent 1667-1676
Origin https://dx.doi.org/10.2174/1871527313666141130204300
Access rights Closed access
Type Article
Web of Science ID WOS:000348594400006
URI http://repositorio.unifesp.br/11600/43396

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account